Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.

Visco C, Moretta F, Falisi E, Facco M, Maura F, Novella E, Nichele I, Finotto S, Giaretta I, Ave E, Perbellini O, Guercini N, Scupoli MT, Trentin L, Trimarco V, Neri A, Semenzato G, Rodeghiero F, Pizzolo G, Ambrosetti A.

Am J Hematol. 2013 Apr;88(4):277-82. doi: 10.1002/ajh.23396. Epub 2013 Feb 28.

2.

Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.

Karan-Djurasevic T, Palibrk V, Kostic T, Spasovski V, Nikcevic G, Srzentic S, Colovic M, Colovic N, Vidovic A, Antic D, Mihaljevic B, Pavlovic S, Tosic N.

Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):252-60. doi: 10.1016/j.clml.2012.03.005. Epub 2012 May 4.

PMID:
22560084
3.

High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.

Kotaskova J, Tichy B, Trbusek M, Francova HS, Kabathova J, Malcikova J, Doubek M, Brychtova Y, Mayer J, Pospisilova S.

J Mol Diagn. 2010 May;12(3):328-34. doi: 10.2353/jmoldx.2010.090100. Epub 2010 Mar 12.

4.

Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia.

Hojjat-Farsangi M, Jeddi-Tehrani M, Razavi SM, Sharifian RA, Mellstedt H, Shokri F, Rabbani H.

Cancer Sci. 2009 Dec;100(12):2346-53. doi: 10.1111/j.1349-7006.2009.01341.x. Epub 2009 Sep 2.

5.

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.

Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM.

Blood. 2003 Jun 15;101(12):4944-51. Epub 2003 Feb 20.

6.

Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.

Gladstone DE, Swinnen L, Kasamon Y, Blackford A, Gocke CD, Griffin CA, Meade JB, Jones RJ.

Leuk Lymphoma. 2011 Oct;52(10):1873-81. doi: 10.3109/10428194.2011.585529. Epub 2011 Aug 18.

7.

Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene.

Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stella S, Guida G, Michel A, Crespo M, Laoutaris N, Montserrat E, Anagnostopoulos A, Dighiero G, Fassas A, Caligaris-Cappio F, Davi F.

Blood. 2005 Feb 15;105(4):1678-85. Epub 2004 Oct 5.

8.

Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study.

Bomben R, Dal Bo M, Capello D, Forconi F, Maffei R, Laurenti L, Rossi D, Del Principe MI, Zucchetto A, Bertoni F, Rossi FM, Bulian P, Cattarossi I, Ilariucci F, Sozzi E, Spina V, Zucca E, Degan M, Lauria F, Del Poeta G, Efremov DG, Marasca R, Gaidano G, Gattei V.

Br J Haematol. 2009 Feb;144(4):492-506. doi: 10.1111/j.1365-2141.2008.07469.x. Epub 2008 Nov 19.

PMID:
19036101
9.

IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine.

Abramenko I, Bilous N, Kryachok I, Filonenko I, Pilipenko G, Chumak A, Bazyka D, Bebeshko V.

Exp Oncol. 2007 Sep;29(3):226-30.

PMID:
18004251
10.

IGHV gene rearrangements as outcome predictors for CLL patients: experience of Ukrainian group.

Kryachok I, Abramenko I, Bilous N, Chumak A, Martina Z, Filonenko I.

Med Oncol. 2012 Jun;29(2):1093-101. doi: 10.1007/s12032-011-9872-5. Epub 2011 Mar 4.

PMID:
21503826
11.

FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.

Li FJ, Ding S, Pan J, Shakhmatov MA, Kashentseva E, Wu J, Li Y, Soong SJ, Chiorazzi N, Davis RS.

Blood. 2008 Jul 1;112(1):179-87. doi: 10.1182/blood-2008-01-131359. Epub 2008 Feb 26.

12.

Immunoglobulin gene rearrangements and mutational status in argentinian patients with chronic lymphocytic leukemia.

Stanganelli C, Travella A, Bezares R, Slavutsky I.

Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):447-457.e2. doi: 10.1016/j.clml.2013.02.019. Epub 2013 May 9.

PMID:
23665144
13.

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ.

Blood. 2008 Sep 1;112(5):1923-30. doi: 10.1182/blood-2007-05-092882. Epub 2008 Jun 24.

14.

Mutation pattern of paired immunoglobulin heavy and light variable domains in chronic lymphocytic leukemia B cells.

Ghiotto F, Marcatili P, Tenca C, Calevo MG, Yan XJ, Albesiano E, Bagnara D, Colombo M, Cutrona G, Chu CC, Morabito F, Bruno S, Ferrarini M, Tramontano A, Fais F, Chiorazzi N.

Mol Med. 2011;17(11-12):1188-95. doi: 10.2119/molmed.2011.00104. Epub 2011 Jul 13.

15.

Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.

Lech-Maranda E, Grzybowska-Izydorczyk O, Wyka K, Mlynarski W, Borowiec M, Antosik K, Cebula-Obrzut B, Makuch-Lasica H, Nowak G, Klimkiewicz-Wojciechowska G, Wawrzyniak E, Bilinski P, Robak T, Warzocha K.

Arch Immunol Ther Exp (Warsz). 2012 Dec;60(6):477-86. doi: 10.1007/s00005-012-0197-7. Epub 2012 Sep 4.

PMID:
22945689
16.

Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.

Morabito F, Mosca L, Cutrona G, Agnelli L, Tuana G, Ferracin M, Zagatti B, Lionetti M, Fabris S, Maura F, Matis S, Gentile M, Vigna E, Colombo M, Massucco C, Recchia AG, Bossio S, De Stefano L, Ilariucci F, Musolino C, Molica S, Di Raimondo F, Cortelezzi A, Tassone P, Negrini M, Monti S, Rossi D, Gaidano G, Ferrarini M, Neri A.

Clin Cancer Res. 2013 Nov 1;19(21):5890-900. doi: 10.1158/1078-0432.CCR-13-0622. Epub 2013 Sep 13.

17.

IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.

Bulian P, Rossi D, Forconi F, Del Poeta G, Bertoni F, Zucca E, Montillo M, Pozzato G, D'Arena G, Efremov DG, Marasca R, Lauria F, Gaidano G, Gattei V, Laurenti L.

J Transl Med. 2012 Jan 30;10:18. doi: 10.1186/1479-5876-10-18.

18.
19.

The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.

Gladstone DE, Blackford A, Cho E, Swinnen L, Kasamon Y, Gocke CD, Griffin CA, Bolaños-Meade J, Jones RJ.

Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):132-7. doi: 10.1016/j.clml.2011.12.005. Epub 2012 Jan 28.

20.

Surface antigen expression and correlation with variable heavy-chain gene mutation status in chronic lymphocytic leukemia.

Vilpo J, Tobin G, Hulkkonen J, Hurme M, Thunberg U, Sundström C, Vilpo L, Rosenquist R.

Eur J Haematol. 2003 Jan;70(1):53-9.

PMID:
12631259
Items per page

Supplemental Content

Write to the Help Desk